 |
인쇄하기
취소
|
Green Cross to conduct phase 1 trial for MGAH22 in HER2-positive carcinoma
Green Cross Corp. says it will conduct phase 1 study for MGAH22 (trastuzumab) after approval of the Korea Food and Drug Administration on October 8.
Developed by the U.S. based MacroGenics Inc., MGAH22 is a next-generation, Fc-optimized monoclonal antibody (mAb) that targets HER2. Based on an observation that different genotypes of FcγR within the patient population lead to different duratio...
Developed by the U.S. based MacroGenics Inc., MGAH22 is a next-generation, Fc-optimized monoclonal antibody (mAb) that targets HER2. Based on an observation that different genotypes of FcγR within the patient population lead to different duratio...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.